Biotech Values

[mcbio]

LOXO

Anyone here follow LOXO? Comments?

Their entire pipeline was in-licensed from ARRY. Why would ARRY give up the bulk of rights to these drugs if they're so promising? That's my first question. (I realize they're early stage and ARRY has more advanced drugs to deal with I suppose but I still think it's something to consider.) Also, beyond the Trk inhibitor, what is so special about the rest of LOXO’s pipeline? How are they differentiated from the myriad of other RET, FGFR, and FLT3 inhibitors out there?

Market cap is small at just over $200M so that's not to say that the Trk inhibitor alone couldn't move shares if it shows good data in the clinic since it's a fairly novel target and I don't think there are a lot of other players involved here.